Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients.

ABSTRACT: In BRAF wild type advanced melanoma, immune checkpoint blockers such as anti-PD1 (anti-programmed cell death 1) are usually continued beyond progression for a hypothetical rare further response. Chemotherapy as a second-line option is considered ineffective by many practitioners based on historical data. Continuing anti-PD1 beyond progression has a high health-economic impact and is not recommended by the FDA. This study aimed to describe the efficacy and survival of advanced melanoma patients who received second-line (or more) chemotherapy after immunotherapy failure.This was a retrospective single center study conducted in a French University Hospital during an 11-month period. All advanced melanoma patients treated with chemotherapy after immunotherapy failure were included.Eighteen pat

SUBMITTER: Saint-Jean M 

PROVIDER: S-EPMC7373626 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature